Jul 03, 2024
Scinai Immunotherapeutics Granted Extension by Nasdaq Hearing Panel to Regain Compliance with Continued Listing Requirements
Jul 02, 2024
Scinai Publishes Q1 2024 Financial Results and Provides Business Update
Jun 13, 2024
Scinai Immunotherapeutics Announces Receipt of a Letter of Intent from the European Investment Bank Providing Specific Terms for Conversion of its Loan to Equity.
Jun 07, 2024
Scinai Immunotherapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement; Continues to Work with the European Investment Bank to Convert Loan to Equity to Regain Compliance with Nasdaq Minimum Shareholders' Equity Requirement
May 15, 2024
Scinai Publishes FY 2023 Financial Statements, Files Annual Report on Form 20-F and Provides Business Update
May 06, 2024
Scinai Immunotherapeutics Announces Receipt of Nasdaq Delisting Notification and Appeal
Apr 10, 2024
Scinai to showcase its novel biological local therapeutic for Plaque Psoriasis at Dermatology Drug Development Summit together with Prof. Michael Schön of UMG
Apr 08, 2024
Scinai Immunotherapeutics' CDMO Unit Selected by Ayana Pharma to Provide Drug Development and cGMP Manufacturing Services
Mar 12, 2024
Scinai leadership to attend BIO-Europe Spring 2024
Feb 29, 2024
Scinai to showcase its cGMP biologics CDMO and innovative NanoAb pipeline at MIXiii 2024
Feb 13, 2024
Scinai Welcomes Liat Halpert as Head of Business Development and Sales
Jan 25, 2024
Scinai Immunotherapeutics Congratulates its Co-Lead Scientific Research Collaborator Dirk Görlich on Louis-Jeantet Prize
Jan 04, 2024
Scinai Immunotherapeutics Announces Closing of Exercise of Outstanding Warrants for $1.69 Million in Gross Proceeds
Jan 04, 2024
Scinai Immunotherapeutics CEO Issues Letter to Shareholders